Merck Gains Repeated FDA Labeling Approvals for VARIVAX Dual-Formulation Varicella Vaccine

For QA directors managing post-approval change programs, Merck Sharp & Dohme LLC's VARIVAX regulatory record offers a direct case study in the sustained lifecycle management demands of a dual-formulation biological product. The varicella virus vaccine live (STN: BL 103552) has accumulated at least six discrete FDA approval letters between 2017 and 2023, each reflecting iterative labeling or storage-condition updates across its refrigerated and frozen presentations.

The most recent approvals, dated February 27, 2023 and August 21, 2023, follow a November 3, 2022 action covering both formulations simultaneously. A January 2019 approval letter explicitly addressed an update to package insert labeling regarding storage conditions for VARIVAX, signaling that cold-chain parameters for biological products remain an active regulatory variable well after initial licensure. Each approval letter is accompanied by distinct package inserts and patient information documents for the refrigerated and frozen presentations, underscoring the documentation burden of maintaining parallel formulation dossiers.

For regulatory affairs leads, the pattern across this dossier illustrates how post-approval supplements under 21 CFR Part 601 can accumulate across a product's commercial life, particularly where storage and handling specifications intersect with evolving stability data or distribution requirements. Managing two formulations under a single BLA requires version-controlled labeling systems capable of tracking divergent package insert histories without cross-contamination of approved text.

The clinical review memo and statistical review documents associated with the February 2023 action suggest at least one supplement in this cycle carried a clinical or analytical data package, not merely an administrative label revision. QA teams should note that the regulatory record distinguishes between approval types, and each carries its own CAPA and change-control implications under ICH Q10 pharmaceutical quality system principles.

With supporting documents older than three years archived separately by FDA, plant heads and QA leads maintaining VARIVAX manufacturing site files will need to ensure their internal document management systems align with the full approval chronology, not only the most recent labeling versions.

The August 2023 approval letter represents the current labeling baseline for VARIVAX, and any subsequent post-approval change will extend a regulatory timeline that now spans at least nine documented FDA actions.

Source: FDA Vaccines, Blood & Biologics / What's New RSS Feed, June 24, 2026.